Search Results for: insulin

This study uses data from IQVIA’s National Prescription Audit to assess the association of the Inflation Reduction Act’s cap on cost sharing with insulin fills.

Published in JAMA, the findings from USC and University of Wisconsin–Madison researchers suggest the policy cut the number of Medicare enrollees who weren’t filling insulin because of cost.

The drugmaker’s move responded to the growing competition that has shaken up the insulin market in recent years.

In the long term, capping insulin payments at $35 a month is just shuffling the deck rather than changing the game of insulin costs.

Congress should take advantage of the current political climate and start reining in the intermediaries in the drug distribution system.

Recent US media and policy attention on insulin affordability has focused on the role of manufacturers in setting prices; however, the role of other drug distribution intermediaries in determining prices has received less attention.

Schaeffer research offers one of the most comprehensive looks at the insulin distribution chain and shows which players are profiting, and by how much, from selling insulin.

Despite its discovery nearly 100 years ago, insulin’s list price has been going up, not down. Schaeffer Center researchers analyzes the flow of money across all distribution system participants—manufacturers, wholesalers, pharmacies, pharmacy benefit managers (PBMs), and health plans.